LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical trials for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pfizer drug takes on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called PF-07248144, alone or combined with other cancer treatments, in people with advanced breast, prostate, or lung cancers that have not responded to standard therapy. The trial aims to find safe doses and check for early signs of tumor shrinkage. A…
Matched conditions: LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for HER2-positive lung cancer: targeted drug combo enters human testing
Disease control Recruiting nowThis early-stage study is testing whether a targeted cancer drug (trastuzumab deruxtecan) combined with immunotherapy and sometimes chemotherapy is safe for people with advanced HER2-positive non-small cell lung cancer. About 304 participants will receive different drug combinati…
Matched conditions: LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail aims to shrink lung tumors
Disease control Recruiting nowThis phase 2 trial tests an experimental drug called FH-006 combined with other cancer treatments in 200 people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. Researchers will also determine the best dose for future …
Matched conditions: LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill hopes to shrink lung tumors in early trial
Disease control Recruiting nowThis early-stage study tests a new tablet, AST2303, in 120 people with advanced non-small cell lung cancer that has spread. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or slow the disease. Participants will take…
Matched conditions: LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New pill HRS-4508 targets tough lung cancers
Disease control Recruiting nowThis study tests a new drug called HRS-4508 in people with advanced non-small cell lung cancer that has not responded to or cannot tolerate standard treatments. About 120 participants will take the drug as a tablet. Researchers will check how safe it is and whether it shrinks tum…
Matched conditions: LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug cocktail hopes to tackle tough lung cancer
Disease control Recruiting nowThis Phase 2 trial is testing a new drug called HRS-4508, given as a tablet, together with other anticancer drugs (SHR-A1811 and/or Adebrelimab) in 100 adults with advanced non-small cell lung cancer that has not responded to standard treatments. The main goals are to check safet…
Matched conditions: LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo therapy aims to tackle tough lung cancer
Disease control Recruiting nowThis phase 2 trial is testing whether combining the experimental drug SHR2554 with other anti-tumor treatments can safely shrink tumors in people with advanced non-small cell lung cancer that cannot be removed by surgery. About 200 participants will receive one of three drug comb…
Matched conditions: LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC